An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine firm, announced its participation in two significant January conferences. The events include Advanced Therapies Week in Miami (January 17-20, 2023) and the 2nd Allogeneic Cell Therapies Summit Europe in London (January 30-February 1, 2023). Key presentations by COO Maia Hansen and VP Dr. Sarah Busch will focus on supply chain logistics and MultiStem® cell therapy for neurological indications, respectively. For further details, visit the event websites linked in the press release.
Positive
None.
Negative
None.
CLEVELAND--(BUSINESS WIRE)--
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in two January conferences, Advanced Therapies Week presented by Phacilitate from January 17-20, 2023 in Miami, FL and the 2nd Allogeneic Cell Therapies Summit Europe from January 30-February 1, 2023 in London, UK.
Ms. Maia Hansen, Chief Operating Officer, and Dr. Sarah Busch, Vice President of Regenerative Medicine, will be participating in talks during Advanced Therapies week in Miami, FL.Ms. Hansen has been invited to chair the session titled, “What Does a Global Supply Chain Look Like for CGT? Defining End-To-End Logistics,” on January 18th. During this session, Ms. Hansen will also be giving a presentation titled, “The Last Mile to the Patient in Cell Therapy.” Dr. Busch will be giving a presentation on January 20th titled, “MultiStem®Cell Therapy for Neurological Indications.” Each will be speaking in their areas of expertise, attending the conference to collaborate and network with leaders across the advanced therapies industry.
The following are specific details regarding the Athersys presentations during Advanced Therapies Week:
Event:
The Last Mile to the Patient in Cell Therapy
Date:
Wednesday, January 18, 2023
Time:
11:05 AM Eastern Time
Location:
Miami Beach Convention Center, 1901 Convention Ctr Dr, Miami Beach, FL 33139
Event:
MultiStem®Cell Therapy for Neurological Indications
Date:
Friday, January 20, 2023
Time:
9:50 AM Eastern Time
Location:
Miami Beach Convention Center, 1901 Convention Ctr Dr, Miami Beach, FL 33139
Additionally, from January 30-February 1, Dr. Manal Morsy, Executive Vice President and Head of Global Regulatory Affairs, will be attending and speaking at the 2nd Allogeneic Cell Therapy Summit Europe. Dr. Morsy will be participating on a panel on January 31st titled, “Understanding the Regulatory Landscape for Allogeneic Cell Therapy Products to Aid Forward Planning and Goals.” Details on this presentation are as follows. Please visit https://allogeneic-cell-therapies-europe.com/ for additional information and registration.
Event:
Understanding the Regulatory Landscape for Allogeneic Cell Therapy Products to Aid Forward Planning and Goals
Date:
Tuesday, January 31, 2023
Time:
2:00 PM Greenwich Mean Time
Location:
Marriott London Canary Wharf, 22 Hertsmere Rd, London E14 4ED
About Athersys
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys. Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
About MultiStem®
MultiStem® (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem therapy’s potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent tolerability demonstrated in clinical studies, we believe that MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.
Athersys Ellen Gurley Manager of Corporate Communications and Investor Relations
ir@athersys.com
LHA Investor Relations
Tirth T. Patel 212-201-6614
tpatel@lhai.com
Source: Athersys, Inc.
FAQ
What events is Athersys participating in January 2023?
Athersys is participating in Advanced Therapies Week in Miami from January 17-20 and the 2nd Allogeneic Cell Therapies Summit Europe in London from January 30-February 1.
Who will represent Athersys at the Advanced Therapies Week?
Ms. Maia Hansen and Dr. Sarah Busch will represent Athersys at the Advanced Therapies Week.
What is Maia Hansen's presentation topic at Advanced Therapies Week?
Maia Hansen's presentation is titled 'The Last Mile to the Patient in Cell Therapy.'
When is Dr. Sarah Busch's presentation scheduled?
Dr. Sarah Busch's presentation on 'MultiStem® Cell Therapy for Neurological Indications' is scheduled for January 20, 2023.
What is the focus of Dr. Manal Morsy's participation in the London summit?
Dr. Manal Morsy will discuss 'Understanding the Regulatory Landscape for Allogeneic Cell Therapy Products' on January 31, 2023.
